The CDC website now says: “The claim ‘vaccines do not cause autism’ is not an evidence-based claim…” Psychologist David Myers from Hope College summarizes the relevant evidence.
You are an educated reader, so I know that you know that vaccines do not cause autism. However, you probably have also read headlines such as the recent U.S. Health and Human Services release, “Autism Epidemic Runs Rampant.”
The rising incidence of LC underscores the pressing need for more effective treatment strategies. Cryoablation has emerged as a promising approach for various cancers, including non-small-cell lung cancer (NSCLC) [11,12,24]. A recent meta-analysis by Xu et al. (2023) found that cryoablation for the treatment of NSCLC was superior to radiofrequency ablation, with improved disease-free survival time, along with fewer complications and a significant reduction in recurrence rates [6]. While effective, an understanding of the MLT is necessary to assure that lung cancer destruction remains unknown. Several clinical studies have suggested an MLT in the −20 °C to −35 °C range [24,25,26]. Accordingly, in this study we utilized the A549 cell line as a model to investigate the response of lung adenocarcinoma carcinoma cells to freezing in an effort to identify the MLT. Additionally, we investigated the effect of combining cryoablation with gemcitabine, a standard chemotherapy drug as a potential adjunctive treatment path for NSCLC.
Understanding the MLT is crucial for optimizing cryoablation protocols. While previous studies have investigated MLT for various cancers, defining it for LC remains open due to the complex nature of lung tissue and varying responses to freezing. The results of this study demonstrate that A549 cells were effectively destroyed following a: single freeze ≤−25 °C; repeat freeze to −25 °C; combination treatment with a single freeze ≤−20 °C; and combination treatment with a repeat freeze ≤−15 °C (Figure 1 and Figure 3). Our reported lethal temperature of −25 °C for a repeat 5 min freeze is comparable to other published data [24] as well as other cancer types, which range from −20 °C to −40 °C [18,19,21,33,58]. Further, studies have shown that translation of the MLT as determined in in vitro studies translates well into in vivo application. For instance, Snyder et al.
One of the most important members of this enlightened club is the philosopher Jean Baudrillard – even though his reputation over the past couple of decades has diminished to an association with a now bygone era when fellow French theorists such as Roland Barthes and Jacques Derrida reigned supreme.
In writing our new biography of Baudrillard, however, we have been reminded just how prescient his predictions about modern technology and its effects have turned out to be. Especially insightful is his understanding of digital culture and AI – presented over 30 years before the launch of ChatGPT.
Back in the 1980s, cutting-edge communication technology involved devices which seem obsolete to us now: answering machines, fax machines, and (in France) Minitel, an interactive online service that predated the internet. But Baudrillard’s genius lay in foreseeing what these relatively rudimentary devices suggested about likely future uses of technology.
An experimental drug compound could prevent and treat some complications of diabetes, such as poor wound healing and rampant inflammation. And it works regardless of blood sugar control, a new study in mice and human cells suggests.
The cornerstone of diabetes care is keeping blood sugar in check through diet and exercise, by maintaining a healthy weight, and by injecting the hormone insulin to help shuttle glucose out of the bloodstream. But while maintaining blood sugar levels in a target range reduces the chance that diabetes complications will emerge, it doesn’t eliminate the risk.
Today, the European Space Agency’s Argonaut lunar lander programme welcomes new members to its growing family. At ESA’s European Astronaut Centre (EAC) near Cologne, Germany, Thales Alenia Space Italy – the prime contractor for Argonaut’s first lander – signed agreements with Thales Alenia Space in France, OHB in Germany, and Thales Alenia Space and Nammo in the United Kingdom.
Argonaut represents Europe’s autonomous, versatile and reliable access to the Moon. Starting with the first mission in 2030, Argonaut landers will be launched on Ariane 6 rockets, each delivering up to 1.5 tonnes of exploration-enabling cargo to the Moon’s surface, from scientific instruments and rovers to vital resources for astronauts such as food, water and air.
Earlier this year, ESA selected Thales Alenia Space Italy to lead the development of the first Argonaut lander, or Lunar Descent Element. Today’s signing ceremony took place in a symbolic location: the LUNA analogue facility at EAC, home to a full-scale Argonaut model – a tangible vision of Europe’s future presence on the Moon.
Plasticity of RNA-binding proteins in cancer.
Extensive research has shown that RNA-binding proteins (RBPs) can influence all cancer hallmarks via post-transcriptional regulation of gene expression.
Many RBPs are considered to be prognostic markers in cancer, and are emerging as important targets for therapeutic intervention through the development of drugs targeting RBPs.
Multiple RBPs play contrasting roles across cancer contexts and can facilitate or suppress cancer depending on the type, subtype, or stage of cancer.
The ability of an RBP to bind to a substrate, and the consequences of binding, are highly dependent on cell type-specific modifications of RBPs, their substrates, and interacting regulatory proteins and RNAs. https://www.cell.com/trends/cancer/fulltext/S2405-8033(25)00253-5 https://sciencemission.com/plasticity-of-RBPs-in-cancer
RNA-binding proteins (RBPs) govern RNA-based post-transcriptional processes that generate the abundance and diversity of the proteome. RBPs have recently emerged as crucial cancer regulators that can influence multiple cancer hallmarks. However, many RBPs display remarkable variations across different tumor types and can exert both tumor-promoting and tumor-suppressive effects. These opposing roles are often attributed to context-dependency, but there is a distinct lack of clarity regarding what aspects of cellular context define the differences in the roles of RBPs. Given the recent development of RBP-targeted interventions, resolving this significant gap in the field could improve the selectivity and specificity of RBP biomarkers and therapies in cancer.
A meta-analysis of RCTs found high uptake (92%) but moderate adherence (62%) to mental health apps among participants with depression or anxiety; posttest attrition averaged 18% and follow-up attrition 28%. Trials that included reminders, human contact, and omitted gamification saw lower dropout rates.
Question What are the expected rates of uptake, attrition, and adherence in randomized clinical trials of mental health apps for depression and anxiety?
Findings This systematic review and meta-analysis of 79 randomized trials found high rates of app uptake (94%) and moderate adherence (62%) among participants with depression or anxiety. Posttest attrition averaged 17%, and follow-up attrition was 27%.
Meaning These findings highlight the need to optimize app design and trial protocols to improve engagement and reduce attrition in digital interventions for depression and anxiety.